Highlights from the IASLC 17th Annual Targeted Therapies of the Treatment of Lung Cancer - 100038

Spotlight
Video

Highlights from the IASLC 17th Annual Targeted Therapies of the Treatment of Lung Cancer

patientpower has 2417 videos Subscribe Here

Loading........
Description: Will targeted therapies for lung cancer include mutation drivers other than ALK and EGFR? Recently returned from the 17th annual IASLC Targeted Therapy Meeting, Dr. Paul Bunn of the University of Colorado, discusses the highlights with stage IV Lung Cancer survivor and patient advocate, Janet Freeman-Daily. Together they explore how to get molecular testing, new IASLC guidelines, and options for getting involved in Clinical Trials.

Produced by Patient Power and Antidote in association with the Precision Medicine for Me Initiative.

Get email alerts | http://www.patientpower.inf...

Subscribe on YouTube | http://www.youtube.com/pati...
Like on Facebook | http://www.fb.com/patientpo...
Follow on Twitter | http://www.twitter.com/pati...
Follow on Google+ | http://www.google.com/+pati...
Shared By : patientpower
Posted on : 03/31/17
Added : 11 months ago